C百奥(688796)上市首日上涨146.63%，换手率达75.80%，成交额为16.71亿元。 力 | | 新 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 301584 | 建发致 | 2025.09.25 | 418.58 | 4714.25 | 2.56 | 0.00 | （文章来源：证券时报网） 证券时报·数据宝统计显示，融资融券交易方面，该股上市首日融资买入额为1.23亿元，占该股全天交易 额的7.39%，最新融资余额为1.11亿元，占流通市值的比例为4.72%。 | 代码 | 简称 | 上市日期 | 上市首日涨跌 | 上市首日融资余额 | 占流通市值比 | 上市首日融券余额 | | --- | --- | --- | --- | --- | --- | --- | | | | | （%） | （万元） | 例（%） | （万元） | | 688796 | C百奥 | 2025.12.10 | 146.63 | 11136.70 | 4.72 | 0.00 | | 688795 | C摩尔 U | 2025.12.05 | 42 ...

Group 1 - The core viewpoint of the article highlights the successful listing of N百奥, with an opening price of 58.00 yuan, reflecting a significant increase of 117.39% on its first trading day [2] - The company specializes in gene editing technology, providing innovative model animals and preclinical pharmaceutical research services, utilizing its proprietary RenMice platform for large-scale drug discovery and development [2] - N百奥 has developed into a comprehensive enterprise over the past decade, focusing on gene-edited model animal production, innovative model animal breeding, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [2] Group 2 - The total issuance of shares for N百奥 was 47.50 million, with an online issuance of 11.46 million shares at a price of 26.68 yuan per share, resulting in a high issuance price-to-earnings ratio of 519.12, compared to the industry average of 39.31 [3] - The effective subscription number for the online issuance reached 6.03 million households, with a final winning rate of 0.02801388% [3] - The funds raised, totaling 1.267 billion yuan, will primarily be allocated to early drug development service platform construction, working capital, preclinical and clinical research projects, and antibody drug research and evaluation projects [3]

Core Viewpoint - The new share issuance results of Bai'ao Saitou indicate strong demand from offline investors, while online investors showed a low abandonment rate, reflecting overall positive market sentiment towards the company’s stock [1][2][3] Summary by Category Share Issuance Results - The total number of shares issued by the company was 47.50 million, with an issuance price of 26.68 yuan per share [3] - Online investors subscribed for 11.42 million shares, amounting to 304.68 million yuan, while offline investors subscribed for 27.15 million shares, totaling 724.27 million yuan [2][3] - The abandonment rate for online subscriptions was 0.36%, with 4.12 thousand shares abandoned, amounting to 109.98 thousand yuan [1][2] Subscription Details - The final online issuance volume accounted for 24.13% of the total issuance, with a final online winning rate of 0.028% [3] - Offline investors fully subscribed, and the number of shares abandoned by online investors was fully underwritten by the lead underwriter, representing 0.09% of the total issuance [1][3] Recent Trends in New Share Issuance - In the past month, notable companies with high online subscription abandonment included C China Uranium, Nanfang Digital, and Hai'an Group, with abandonment rates of 0.71%, 0.40%, and 0.38% respectively [3] - Bai'ao Saitou's abandonment rate of 0.36% places it among the companies with lower abandonment rates in recent new share issuances [3]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to return to A-share market after successfully passing the listing review by the Shanghai Stock Exchange, marking its A+H listing strategy [1] Group 1: Company Overview - Baiaosaitu, established in 2009, is a preclinical CRO and biotechnology company that provides innovative model animals and preclinical drug development services based on its proprietary gene editing technology [1] - The company has developed a comprehensive platform that includes gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Achievements - As of the reporting period, Baiaosaitu has completed over 5,100 customized gene editing projects and developed more than 3,500 types of RenMice and other gene-edited animals and cell line models [2] - The company has established partnerships with numerous renowned biotech and pharmaceutical companies for antibody drug discovery, leveraging its RenMice platform and "thousands of mice, ten thousand antibodies" approach [2] Group 3: Financial Performance - From 2022 to 2024, Baiaosaitu's revenue is projected to be 534 million yuan, 717 million yuan, and 980 million yuan, with a compound annual growth rate of 35.56% [3] - The net profit for the same period is expected to be -602 million yuan, -383 million yuan, and 33.54 million yuan, indicating a turnaround to profitability in 2024 [3] Group 4: IPO and Fundraising - Baiaosaitu plans to raise 1.185 billion yuan through its IPO, which will be directed towards enhancing its existing business and core technologies [3] - The fundraising will support projects aimed at expanding the production capacity of model animals, improving early drug discovery capabilities, and enriching the preclinical research pipeline [3]